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ABSTRACT: The present study describes the biophysical characterization of
generation-five poly(amidoamine) (PAMAM) dendrimers conjugated with
riboflavin (RF) as a cancer-targeting platform. Two new series of dendrimers
were designed, each presenting the riboflavin ligand attached at a different site
(isoalloxazine at N-3 and D-ribose at N-10) and at varying ligand valency.
Isothermal titration calorimetry (ITC) and differential scanning calorimetry
(DSC) were used to determine the binding activity for riboflavin binding
protein (RfBP) in a cell-free solution. The ITC data shows dendrimer conjugates have KD values of ≥465 nM on a riboflavin
basis, an affinity ∼93-fold lower than that of free riboflavin. The N-3 series showed greater binding affinity in comparison with
the N-10 series. Notably, the affinity is inversely correlated with ligand valency. These findings are also corroborated by DSC,
where greater protein−conjugate stability is achieved with the N-3 series and at lower ligand valency.

■

INTRODUCTION
Multivalency provides the biophysical basis for the mechanism
of cell targeting in targeted drug delivery.1−6 The targeting
effectiveness of the delivery system is frequently predicted by
determining its avidity constant in vitro, a collective property
that measures the strength of multivalent association between
multiple receptor−ligand pairs.3 However, the affinity constant
that measures the strength of the monovalent interaction for an
independent receptor−ligand pair is far less studied despite its
direct influence on the avidity. In this Article, we investigate the
biophysical aspects of monovalent interactions with a cancertargeting system comprising the riboflavin (RF)-presenting
multivalent dendrimer7 and the soluble RF receptor. We
address the thermodynamic parameters, affinity, and stability as
a function of design factors including ligand valency and
orientation. The present study strongly suggests that evaluation
of monovalent interactions also provides important information
that should be taken into consideration in the design process of
a multivalent delivery system.
Recent advances in nanotechnology have led to the discovery
of various multifunctional platforms applicable for targeted drug
delivery in many critical therapeutic areas from cancers to
inflammatory diseases.8−13 These delivery platforms are
typically composed of a nanometer-sized carrier conjugated
with multiple copies of a cell targeting ligand and also a payload
of small molecule chemotherapeutics, therapeutic genes, and
imaging agents. Multifunctional platforms enable selective
uptake of the payload by pathological cells and therefore
improve their therapeutic indices of treatments.8−13 Applica© 2011 American Chemical Society

tions of this approach for anticancer therapeutic molecules have
been extensively investigated by the targeting of cancer-specific
surface biomarkers such as folic acid receptor-α (FARα),14,15 RF
receptor,7,16 αvβ3 integrin,2,17,18 prostate-specific membrane
antigen,19 Her2 receptor, 20 transferrin receptor, 21 and
epidermal growth factor receptor.20,22,23
We have recently begun to explore RF as a small molecule
ligand for the targeted delivery of anticancer therapeutic
agents.7,16 RF receptors are overexpressed in certain cell lines
including human breast and prostate cancers, and this family of
proteins potentially constitutes one type of tumor biomarker.24,25 In our previous approach, we designed a novel
delivery platform based on a fifth-generation (G5) poly(amidoamine) (PAMAM) dendrimer26,27 conjugated with the
RF ligand (Figure 1), which demonstrated the targeted delivery
of the anticancer drug methotrexate (MTX) in KB cancer cells
in vitro.7 This preliminary work points to the possibility of
other similar applications against cancer cells that overexpress
the RF receptors.
Here we were interested in investigating the basic design
principles of a RF-conjugated PAMAM dendrimer by using
biophysical techniques to identify its optimal design features.
We focused on two design factors, ligand orientation and
valency, because they are known to make significant
contributions to controlling the avidity of the multivalent
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receptor interactions. It is thus different from the avidity
constant, a collective property that indicates the strength of the
multivalent interaction as previously noted.3 The avidity can be
measured by several biophysical methods including SPR
spectroscopy1,16 and cell-based fluorescence assays.7,30 Such
methods have already demonstrated the positive correlation
between the avidity and the ligand valency.1,2,8,31−33 Despite
the advantages for measuring such collective properties, each of
these methods has limitations in providing direct information
on the strength of discrete monovalent interactions. This
Article employs two other complementary techniques,
isothermal titration calorimetry (ITC) and differential scanning
calorimetry (DSC), to address the thermodynamic aspects of
the monovalent receptor−ligand interactions for two series of
RF-conjugated dendrimers, each having a variable valency of
the ligand attached at a different RF site (N-3, N-10). Here we
report the identification of a preferred position for the RF
attachment, and an optimal range of ligand valency. More
notably, we find that the affinity for the RF ligand decreases
significantly both upon its covalent attachment to the
dendrimer and as a function of ligand valency.

■

EXPERIMENTAL SECTION

Materials. RF binding protein, apo-form was purchased from
Sigma-Aldrich (CAS 91386-80-0). Phosphate-buffered saline (PBS)
and 1.0 M phosphate buffer were purchased from Sigma-Aldrich.
(−)-RF (purity ≥98%) and fluorescein 5(6)-isothiocyanate (FITC;
purity ∼90%) were purchased from Sigma-Aldrich. G5 poly(amidoamine) (PAMAM) dendrimer was purchased as a 17.5% (w/
w) methanol solution (Dendritech, Midland, MI). The PAMAM
dendrimer was purified by dialysis prior to use as described
elsewhere.34
General Synthetic Methods. All solvents and reagents were
purchased from commercial suppliers and used without further
purification. Characterization of compounds was typically carried out
by nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and UV/vis spectrometry. For the NMR measurement, each
sample was dissolved in a deuterated solvent (CD3OD, D2O), and its
1
H NMR spectrum was acquired with a Varian NMR spectrometer at
500 MHz under a standard observation condition. The molecular
weights for a fifth-generation PAMAM dendrimer and its RF
conjugates were measured by matrix-assisted laser desorption
ionization-time-of-flight (MALDI TOF) with a Waters TOfsPec-2E
spectrometer, as described elsewhere.35 The spectrometer was masscalibrated with BSA in sinapinic acid, and data were acquired and
processed using Mass Lynx 3.5 software. UV−vis absorption spectra
were recorded on a Perkin-Elmer Lambda 20 spectrophotometer.
The purity of each dendrimer conjugate was determined by HPLC,
which was carried out on a Waters Acquity Peptide Mapping System
equipped with a Waters photodiode array detector (a UPLC
system).35 Each sample solution was run on a C4 BEH column
(150 × 2.1 mm, 300 Å) connected to Waters Vanguard column.
Elution of the conjugate was performed in a linear gradient beginning
with 98:2 (v/v) water/acetonitrile (with trifluoroacetic acid at 0.14 wt
% in each eluent) at a flow rate of 1 mL/min.
Synthesis of G5-N(3)-RFn Conjugates 4−7 (n = 2.8, 4.5, 11.1).
3-Carboxymethylriboflavin 1 was synthesized as described elsewhere.16,36,37 It was first converted to its activated NHS ester form
2 as follows. To a stirred solution of 3-carboxymethylriboflavin (27
mg, 63 μmol) dissolved in DMF (total volume = 5.5 mL) was added
N-hydroxysuccinimide (NHS; 8 mg, 69 μmol), 4-dimethylaminopyridine (DMAP; 8 mg, 69 μmol), and N-(3-dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride (EDC; 13 mg, 69 μmol) in a
sequence. The reaction mixture was stirred at ambient temperature for
12 h. Four separate glass vials were prepared, each containing G5
PAMAM dendrimer (30 mg, 1.1 μmol) dissolved in MeOH (10 mL).
The solution of the activated ester 2 in DMF was divided into four

Figure 1. Structures of RF and two series of RF dendrimer conjugates
used in present study. In each series, the RF ligand is tethered to the
G5 PAMAM dendrimer through a linker located at its N-3 or N-10
position.

ligand.3 First, we attached the RF ligand in two distinct
orientations. This is because the structure of a RF molecule
contains two orthogonal domains, each amenable for chemical
modifications required for the dendrimer conjugation: an N-3
position at an isoalloxazine head and a (D)-ribose unit attached
at the N-10 position (Figure 1). According to the only crystal
structure determined for RF in complex with chicken riboflavin
binding protein (RfBP),28 the xylene domain of the
isoalloxazine head is stacked between hydrophobic planes
comprising the RF binding cleft, and the (D)-ribose unit is
exposed to the aqueous medium. Therefore, either the N-3
position of the isoalloxazine head16 or the primary alcohol at
the (D)-ribose7,29,30 can be utilized as a tethering site. This
structure-guided design strategy suggests the comparison of the
two ligand orientations in terms of the linker attachment: the
N-3 position and the (D)-ribose linked to the N-10 position,
which was already employed in our prior study7 (Figure 1).
The linker length for each RF attachment is relatively short.
However, our prior studies based on cellular binding7 and the
surface plasmon resonance (SPR) study16 demonstrated that
the linker length was long enough for the dendrimer-attached
RF to bind the targeted receptor protein. Second, in each of the
linker series (N-3, N-10), we varied the average number of RF
ligands tethered to the dendrimer to determine how such
variation makes an impact on the dissociation constant (KD) of
the tethered RF ligand to mammalian RfBP acting as the model
receptor.
The dissociation constant (KD) we measured here refers to
the affinity constant for the independent, monovalent ligand−
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μL, 208 μmol), and the final mixture was stirred for 6 h. As an
illustrative method for purification, each reaction mixture was
concentrated in vacuo, and the residue was dissolved in 10 mL of
PBS (pH 7.4). The solution was loaded into a membrane dialysis bag
(MWCO 10 kDa) and dialyzed against PBS (2 × 2 L), and deionized
water (3 × 2 L) over 3 days until its dendrimer purity was greater than
95%, as determined by the anal. HPLC method (Figure S3 of the
Supporting Information). The aqueous solution was collected and
freeze-dried in vacuo to afford the G5-N(10)-RFm as pale-yellow solid:
10 (25 mg), 11 (28 mg), and 12 (30 mg). The number (valency) of
RF ligands attached to the surface of the dendrimer was estimated on a
mean basis by the analysis of 1H NMR, UV/vis, and MALDI mass
spectral data (Table S1 of the Supporting Information). MALDI TOF
mass spectrometry (m/z, g mol−1): 10 (m/z = 33 700); 11 (m/z = 36
900); 12 (m/z = 40 300). UV/vis (PBS, pH 7.2): 10−12: λmax = 449
nm (ε = 12 100 M−1 cm−1 calculated on the basis of RF), 374 nm (ε =
10 300 M−1cm−1 calculated on the basis of RF). 1H NMR (500 MHz,
D2O): 10: δ 7.91−7.57(br s), 4.89−4.88 (br s), 4.85−4.84 (br s),
4.84−4.77 (s), 4.73−4.72 (br s), 4.46−4.39 (br s), 4.32−4.27 (br s),
4.21−4.15 (br s), 4.15−4.08 (br s), 4.02−3.96 (br s), 3.89−3.83 (br s),
3.72−3.67 (br s), 3.52−3.46 (br s), 3.45−3.13 (quint), 2.89−2.76 (s),
2.68−2.58 (s), 2.58−2.53 (br), 2.50−2.32 (s), 2.31−2.27 (br s), 2.25−
2.22 (br), 2.19−2.16 (br), 2.14−2.13 (br s), 2.11−2.09 (br s), 2.05−
2.04 (br s), 2.01−1.95 (s), 1.94−1.86 (br s), 1.86−1.80 (br), 1.27−
1.25 (br s); 11: δ 7.89−7.53 (br s), 5.61−5.49 (br s), 5.42−5.34 (br s),
5.29−5.23 (br s), 4.89−4.87 (s), 4.85−4.76 (br), 4.45−4.37 (br),
4.34−4.27 (br s), 4.22−4.14 (br s), 4.13−4.08 (br s), 4.02−3.95 (br s),
3.90−3.82 (br), 3.72−3.66 (s), 3.54−3.46 (br s), 3.44 3.13 (quint),
2.89−2.77 (s), 2.69−2.59 (s), 2.58−2.53 (s), 2.48−2.36 (s), 2.32−2.27
(br s), 2.25−2.21 (br s), 2.20−2.15 (br), 2.15−2.11 (br s), 2.11−2.09
(br s), 2.05−2.03 (br s), 2.00−1.94 (s), 1.92−1.87 (br s), 1.86−1.77
(br), 1.35−1.32 (br d), 1.26−1.24 (br s), 1.23−1.19 (br s); 12: δ
7.88−7.49 (br s), 5.65−5.52 (br s), 5.44−5.35 (br s), 5.31−5.21 (br s),
5.02−4.97 (br s), 4.95−4.91 (br), 4.89−4.88 (br d), 4.85−4.84 (br d),
4.81−4.79 (d), 4.74−4.71 (br s), 4.68−4.61 (br), 4.48−4.35 (br s),
4.35−4.23 (br s), 4.23−4.13(br s), 4.13−4.03 (br s), 4.02−3.93 (br s),
3.90−3.80 (br s), 3.73−3.63 (s), 3.55−3.45 (br s), 3.40−3.14 (t),
2.91−2.71 (s), 2.71−2.58 (s), 2.58−2.51 (s), 2.51−2.31 (s), 2.31−2.26
(br s), 2.26−2.21 (br s), 2.21−2.12 (br s), 2.05−2.02 (br s), 2.00−1.94
(s),1.93−1.88 (br s), 1.85−1.78 (br s), 1.35−1.32 (br d), 1.26−1.23
(br s). HPLC: 10 (tr = 9.06 min; purity = 99%); 11 (tr = 9.45 min;
purity = 99%); 12 (tr = 9.68 min; purity = 99%).
Isothermal Titration Calorimetry. All experiments were carried out
using a Nano ITC Standard Volume from TA Instruments (Lindon,
UT). Binding conditions were optimized for each dendrimer
conjugate. Experiments were all performed in PBS buffer (pH 7.4).
Buffer was degassed prior to an experiment for 25 min at room
temperature with a stir rate of 610 rpm. In a multiple injection mode,
the experiment was set up using the following parameters: 25 °C, 250
rpm, 500−700 s between injections, 20 injections of 10 μL each. Upon
filling the cell and syringe, stirring was turned on and allowed to
equilibrate for ∼1 h. Experiment was initiated when the baseline power
difference was <0.4 μW within 5 min. Control experiments were
performed with the injection of the dendrimer conjugates into the PBS
buffer. All data were recorded with the TA Instruments software
provided. Further analysis was performed using TA NanoAnalyze
Version 2.1.13. The area under each peak was integrated, and the
resulting data were modeled using an independent model fit with the
three variables, n, ΔH, and KA. Using the fit output of ΔH and KA, ΔG
and ΔS were determined at 25 °C. Statistics were then performed on
the thermodynamic parameters with a desired confidence interval of
95%. Each experiment was repeated 2−8 times, and the average from
multiple runs was used to obtain KD (= 1/KA).
Differential Scanning Calorimetry. DSC measurements were
performed using a Nano DSC from TA Instruments (Lindon, UT).
Experiments were performed in 10 mM phosphate buffer, pH 7.0.
Buffer was degassed prior to each experiment for 25 min at room
temperature with a stir rate of 610 rpm. The sample and reference
were allowed to equilibrate for ∼30 min until stabilization was
achieved. Experiment was initiated when the baseline power difference

aliquots (2, 2, 1, and 0.5 mL), and each aliquot was added to each of
the dendrimer solutions. Each reaction mixture was stirred for 2 days
at rt. For conjugation with fluorescein isothiocyanate (FITC), one of
the reaction mixtures, the one that contained 2 mL of the activated
ester, was further treated by adding FITC (2 mg, 5.7 μmol) dissolved
in methanol (1 mL). This mixture was stirred additionally for 1 day at
rt. After the stirring, each of the above mixtures was treated with acetic
anhydride (24 μL, 250 μmol) and triethylamine (35 μL, 250 μmol),
and the final mixture was stirred for 6 h. As an illustration for a typical
purification method, each reaction mixture was concentrated in vacuo,
and the residue was dissolved in 10 mL of PBS (pH 7.4). The solution
was loaded into a membrane dialysis bag (MWCO 10 kDa) and
dialyzed against PBS (2 × 2 L) and deionized water (3 × 2 L) over 3
days until its dendrimer purity was greater than 95%, as determined by
the anal. HPLC method (Figure S3 of the Supporting Information).
The aqueous solution was collected and freeze-dried to afford the G5N(3)-RFn as pale-yellow solid: 3 (29 mg), 4 (28 mg), 5 (26 mg), and
6 (23 mg). The number (valency) of RF ligands attached to the
surface of the dendrimer was estimated on a mean basis by the analysis
of 1H NMR, UV/vis, and MALDI mass spectral data following the
general method, as described elsewhere (Table S1 of the Supporting
Information).7,35 MALDI TOF mass spectrometry (m/z, g mol−1): 4
(m/z = 33 400); 5 (m/z = 35 300); 6 (m/z = 36 900); 7 (m/z = 38
200). UV/vis (PBS, pH 7.2): 4−6: λmax = 449 nm (ε = 12 100 M−1
cm−1 calculated on the basis of RF), 272 nm (ε = 10 300 M−1 cm−1
calculated on the basis of RF); 7: λmax = 491 nm (ε = 100 000 M−1cm−1
calculated on the basis of FITC). 1H NMR (500 MHz, D2O): 4: δ
8.07−7.88 (br q), 4.55−4.48 (br s), 4.34−4.26 (br s), 3.70−3.67 (br
s), 3.49−3.39 (s), 3.17−3.05 (s), 2.74−2.64 (s), 2.61−2.59 (br s),
2.54−2.51 (quint), 2.51−2.42 (s), 2.27−2.17 (s), 2.03−2.01 (br s),
2.00−1.98 (br s), 1.98−1.97 (br s),1.89−1.88 (br s), 1.84−1.79 (s),
1.66−1.65 (br s); 5: δ 8.19−8.17 (br s), 8.07−7.82 (br q), 4.54−4.49
(br s), 4.34−4.28 (br s), 3.70−3.66 (br s), 3.66−3.64 (br s), 3.59−6.56
(br s), 3.46−3.35 (s), 3.16−3.04 (s), 2.74−3.62 (s), 2.62−3.59 (br s),
2.54−2.50 (s), 2.50−2.41 (s), 2.26−2.17 (s), 1.89−1.87 (br s), 1.83−
1.78 (s), 1.67−1.64 (br s); 6: δ 8.2−8.13 (br s), 8.06−7.77 (t), 5.07−
2.94 (br s), 4.76−2.62 (br s), 4.58−4.44 (br s), 4.35−4.21 (br s),
3.71−3.61 (br d), 3.47−3.34 (s), 3.21−3.02 (s), 2.77−2.62 (s), 2.62−
2.57 (s), 2.56−2.50 (s), 2.50−2.36 (s), 2.29−2.05 (s), 1.87−1.74 (s);
7: δ 8.11−7.8 (br q), 6.71−6.55 (br d), 5.08−4.98 (br s), 4.74−4.64
(br s), 4.54−4.46 (br s), 4.35−4.25 (br s), 4.18−4.13 (br s), 3.71−3.66
(br s), 3.66−3.62 (br s), 3.60−3.54 (br s), 3.45−3.35 (s), 3.16−3.04
(s), 2.73−2.60 (s), 2.60−2.58 (br s), 2.54−2.48 (s), 2.48−2.38 (br s),
2.25−2.13 (s), 1.89−1.87 (br s), 1.83−1.77 (s), 1.33−1.27 (br s),
1.27−1.24 (br s), 0.90−0.85 (br d). HPLC: 4 (tr = 7.70 min; purity =
95%); 5 (tr = 7.79 min; purity = 97%); 6 (tr = 7.91 min; purity =
98%); 7 (tr = 8.30 min; purity = 97%).
Synthesis of G5-N(10)-RFm Conjugates 10−12 (m = 4.0, 7.7,
8.4). A suspension of RF (500 mg, 1.3 mmol) in a mixture of DMSO
(5 mL) and pyridine (10 mL) was stirred at 90 °C until it became
completely dissolved. To this hot solution was added glutaric
anhydride (303 mg, 2.6 mmol) as solid. The mixture was stirred at
the same temperature for 12 h, and it was concentrated in vacuo,
yielding pale brown solid. This residue was thoroughly rinsed with
ether and acetonitrile in multiple times and dried in vacuo to afford 8
as brown foam (472 mg, 73%). This crude product was used for the
conjugation with the PAMAM dendrimer without further treatment.
HRMS (ESI, negative ion mode): calcd for C22H26N4O9 [M-H]−, m/z
= 489.1627 (8), found 489.1620; calcd for C27H32N4O12[M-H]−, m/z
= 603.1938 (a diadduct of glutaric anhydride), found 603.1920.
To a solution of 8 (33 mg, 67 μmol) in DMF (4 mL) was added
NHS (12 mg, 101 μmol), DMAP (16 mg, 135 μmol), and EDD (26
mg, 135 μmol) in a sequence. The reaction mixture was stirred at
ambient temperature for 16 h. Three separate glass vials (20 mL
capacity) were prepared, each containing G5 PAMAM dendrimer (25
mg, 1.0 μmol) dissolved in MeOH (10 mL). The DMF solution
containing the activated ester 9 was divided to three aliquots (0.9, 1.3,
and 1.8 mL), and each aliquot was added to each of the dendrimer
solutions. Each reaction mixture was stirred for 2 d at rt and then
treated with acetic anhydride (20 μL, 208 μmol) and triethylamine (29
509
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remained within a tenth of a microwatt over 5 min. All experiments
were performed at 3 atm pressure. For all scans, the low-temperature
limit was 25 °C and the high temperature limit was 100 °C. The scan
rate was 1.0 °C/min. Scans of the buffer as sample and reference were
measured to determine a baseline. All data were recorded with the TA
Instruments software. To obtain molar heat capacity (MHC) data, the
baseline was subtracted and further analysis was performed using TA
NanoAnalyze Version 2.1.13. Additional calculations used by the
program included inputs on the concentration, molecular mass of the
bound complex, and the apparatus cell volume (0.3 mL). The molar
mass of RfBP was taken as 30 kDa, and the concentration used in all
measurements was 1 mg/mL. Analysis was performed using a twostate scaled model.

and at a variable average valency (n = 0, 2.8, 4.5, and 11.1). This
conjugate series was prepared by the amide coupling of the G5
PAMAM dendrimer with 3-carboxymethylriboflavin (1)36,37
added at variable molar equivalents to the dendrimer. Synthesis
of the conjugate series was performed by an EDC-based
method involving two reactions performed in a sequence (step
i, ii), where 1 was preactivated to its NHS ester 2 prior to the
reaction with the dendrimer. After this coupling step, each of
the unreacted surface amines was converted to N-acetyl amide,
making the dendrimer surface neutral. In this sequential
approach, we controlled the molar ratio between 1 and the
dendrimer G5-(NH2)110 and were able to prepare those RF
conjugates 3−6. The conjugate 7 contains a fluorescent dye
(FITC), an imaging molecule commonly employed for cell
uptake studies. It was introduced to determine if the presence
of the dye molecule itself makes an impact on the binding
affinity of the RF ligand indirectly through a steric effect. This
dye-containing RF dendrimer was prepared through an
additional coupling step (iii) for the FITC prior to the final
exhaustive N-acetylation.
Each RF conjugate was purified by exhaustive dialysis using a
membrane tubing (MWCO 10 kDa), and its purity was in the
range of 95−98%, as determined by the anal. HPLC method in
which the AUC (area under curve at 285 nm) value for each
RF-conjugated dendrimer was compared with that of free RF or
RF ligand (Figure S3 of the Supporting Information). The
molecular mass of the conjugate was measured by the MALDI
mass spectral analysis (m/z, g mol−1): 4 (33 400); 5 (35 300); 6
(36 900); 7 (38 200) (Figure S1 of the Supporting
Information). Each RF conjugate was fully characterized by
employing other relevant analytical techniques including 1H
NMR spectroscopy (Figure 2a, Figure S2 of the Supporting
Information) and UV/vis spectrometry (Figure 2b, Figure S4 of
the Supporting Information). Selected spectral data for the new
conjugates 4−7 are shown in Figure 2. These data provide
evidence of the tethering of the RF ligand to the dendrimer, as
suggested by RF-specific aromatic protons in the 1H NMR
spectra (broad peaks at 7.6 to 8.4 ppm) and by the strong
absorption at longer wavelengths that points to the
isoalloxazine chromophore (λmax = 449 nm; ε = 12 100 M−1
cm−1). The number of RF ligands attached to each dendrimer
conjugate was determined on a mean basis by the analysis of
the 1H NMR, UV/vis, and MALDI mass spectral data, as
summarized in Table S1 of the Supporting Information. The
valency of RF ligands that is referred for each dendrimer
conjugate in this article is, however, based on the 1H NMR
analysis because of its greater accuracy.42,43 The efficiency for
ligand conjugation (no. RF ligand conjugated per dendrimer
relative to no. RF ligand added) was approximately 40−50% for
this series of the conjugates (4 to 7). Such efficiency is
acceptable but lower than that observed frequently in the amide
conjugation of small molecules (>80%). We believe that a
number of factors might be responsible such as steric
congestion on the dendrimer surface34 and decreased reactivity
of dendritic branches due to backfolding.26,27
Second, we designed another series of RF-presenting
dendrimer conjugates G5-RF(10)-RFm 10−12 (Scheme 2) in
which each RF ligand is attached to the dendrimer through a
glutaric acid spacer linked at its N-10 position. To attach the
RF to the spacer, we synthesized a glutaryl derivative of RF 8
(HRMS-ESI, negative ion mode: calcd for C22H26N4O9 [MH]−, m/z = 489.1627, found 489.1620), a covalent adduct
formed by an ester linkage at its hydroxyl group of the (D)-

■

RESULTS AND DISCUSSION
Synthesis of RF-Conjugated PAMAM Dendrimers. The
delivery platform used for this study is based on a G5
poly(amidoamine) (PAMAM) dendrimer (diameter 5.4
nm).27,38 This dendrimer particle has a large number of
primary amines (theoretically 128), each branched repetitively
on its periphery, and each of the amine branches is available for
covalent conjugation with a variety of targeting ligands, making
the dendrimer an excellent system for the multivalent ligand
design.31,39−41 We approached the design of RF-presenting G5
dendrimer conjugates by evaluating two key design factors
(Figure 1): (1) variation of the ligand orientation by presenting
the ligand attached at its N-3 and N-10 position and (2)
variation of the ligand valency (the number of the ligands
attached per dendrimer). First, we designed a series of G5N(3)-RFn conjugates 4−7 (Scheme 1) in which each
dendrimer contains the RF ligand tethered at the N-3 position
Scheme 1. Synthesis of PAMAM Dendrimers 3−7, Each
Conjugated with the RF Ligand at the N-3 positiona

a
Reagents and conditions: (i) N-hydroxysuccinimide, dimethylaminopyridine (DMAP), EDC, DMF, rt, 12 h; (ii) 2 added in variable mol.
equiv to G5 PAMAM dendrimer G5-(NH2)110, MeOH, rt, 3 days; (iii)
fluorescein isothiocyanate (FITC; added for conjugate 7 only), rt, 24
h; and (iv) excess Ac2O, Et3N, 6 h, rt.
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Scheme 2. Synthesis of PAMAM Dendrimers 10−12, Each
Conjugated with RF at N10 Positiona

Figure 2. (a) 1H NMR spectra of RF-conjugated dendrimers G5N(3)-RFn 4−7 and (b) their UV/vis spectra, each measured at 0.1
mg/mL concentration in PBS (pH 7.4).

a

Reagents and conditions: (i) glutaric anhydride, pyridine, DMSO, 90
°C, 12 h; (ii) N-hydroxysuccinimide, dimethylaminopyridine
(DMAP), EDC, DMF, rt, 16 h; (iii) 9 added in variable mol. equiv
to G5 PAMAM dendrimer G5-(NH2)110, MeOH, rt, 2 d; and (iv)
excess Ac2O, Et3N, 6 h, rt.

ribose unit. A number of similar RF conjugation reactions have
been previously reported elsewhere,29,30,44 each suggesting that
the coupling reaction might occur regioselectively at the
primary hydroxyl group, perhaps because it is more sterically
favored than those secondary alcohols located adjacent to the
bulky isoalloxazine head. Synthesis of this N-10 conjugate series
10−12 was performed similarly, as previously illustrated by an
EDC-based coupling method (step ii, iii), followed by the
exhaustive N-acetylation of remaining primary amines.
Each conjugate in this series was purified by the dialysis
method as previously described, and its purity was 99%, as
determined by the anal. HPLC method (Figure S3 of the
Supporting Information). Each RF conjugate was fully
characterized by 1H NMR spectroscopy, UV/vis, and MALDI
mass spectrometry (m/z, g mol−1): 10 (33 700); 11 (36 900);
and 12 (40 300). Ligand valency for each dendrimer conjugate
was determined on a mean basis by the analysis of the 1H
NMR, UV/vis, and MALDI mass spectral data, as summarized
in Table S1 of the Supporting Information.
Distribution of RF Ligands. The amide conjugation
reaction applied for the attachment of RF ligands to the G5
PAMAM dendrimer occurs in a stochastic fashion and
generates a distribution of the numbers of ligands conjugated
per dendrimer.42,43 Figure 3 illustrates the Poissonian
distribution of the ligand-conjugated dendrimers simulated for
the three dendrimer conjugates, each having a mean number of
2.8, 4.5, and 11.1 ligands. For example, 4 G5-N(3)-RFn (n =
2.8) is experimentally determined to have approximately three
RF ligands attached per dendrimer on an average basis. The
stochastic reaction conditions result in a multivalent dendrimer
species (n ≈ 0−8; median ≈ 4) with the highest population at n
= 2. Therefore, it is noted that the thermodynamic parameters

Figure 3. Theoretical distribution of RF ligands attached per
dendrimer acquired by Poissonian simulation. Each of the RFconjugated dendrimer conjugates G5-N(3)-RFn 4−6 has the mean
value of 2.8, 4.5, or 11.1 RF ligands per dendrimer.

we studied here for the effect of the ligand valency are
understood on a mean basis.
Thermodynamic Measurements. We first used ITC to
characterize the thermodynamic response of the dendrimer-RF
conjugate to the RfBP. In our previous study of “free” RF ligand
binding to RfBP, we determined the binding stoichiometry (n)
from ITC to be 1:1, which has also been confirmed by
fluorescence quenching studies.45,46 However, with the RF
conjugated dendrimers, we observe that not all RF sites on the
dendrimer are occupied by RfBP. (See Tables 1 and 2.) On the
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Table 1. Thermodynamic Parameters for the Binding of N-3 RF Dendrimer Conjugates with RfBP in PBS (pH 7.4) at 25°C
na

system (vs RfBP)
3,
4,
5,
6,
7,
a

G5-(RF)0
G5-(RF)2.8
G5-(RF)4.5
G5-(RF)11.1
G5-(RF)11.1-(FI)2

NB
1.76
1.24
1.63
5.11

±
±
±
±

ΔHa (kJ mol−1)

Kd (nM)b
0.06
0.06
0.14
0.51

NB
465 ± 12
568 ± 95
1170 ± 90
2075 ± 243

NB
−41.0
−55.7
−46.5
−13.0

±
±
±
±

2.7
3.8
5.3
2.7

ΔG (kJ mol−1)

−TΔS (kJ mol−1)

NB
−36.2
−35.3
−33.7
−32.2

NB
4.8
20.4
12.8
−19.2

Reported errors are from fitting data. bReported errors are from averaging multiple runs. NB: no binding.

Table 2. Thermodynamic Parameters for the Binding of N-10 RF Dendrimer Conjugates with RfBP in PBS (pH 7.4) at 25°C

a

system (vs RfBP)

na

Kd (nM)b

ΔHa (kJ mol−1)

ΔG (kJ mol−1)

−TΔS (kJ mol−1)

10, G5-(RF)4.0
11, G5-(RF)7.7
12, G5-(RF)8.4

2.88 ± 0.27
5.16 ± 0.76
2.94 ± 0.77

2671 ± 199
4049 ± 13
5551 ± 1064

−15.7 ± 2.3
−9.0 ± 2.2
−13.3 ± 6.1

−31.9
−30.8
−30.0

−16.3
−21.8
−16.7

Reported errors are from fitting data. bReported errors are from averaging multiple runs.

Figure 4. Raw ITC data for the interaction between (a) G5-(RF)4.5 at the N-3 position and (c) G5-(RF)4.0 at the N-10 position with chicken RfBP
(4 μM) at 25 °C in PBS buffer. Plot of integrated area under each injection peak for G5-(RF)4.5 at the N-3 position (b) and G5-(RF)4.0 at the N-10
position (d). The solid line (b and d) is an independent model fit to data with parameters n, KA, and ΔH.

more flexibility via the longer glutarate linker installed at the
ribose terminus of RF were screened, with an average RF
valency of 4.0, 7.7, or 8.4 (conjugates 10−12; Table 2). A
representative ITC curve is shown in Figure 4 for the binding
of G5-(RF)n(= 4 or 4.5) with RfBP at the N-3 position (Figure
4a,b) and the N-10 position (Figure 4c,d). Thermodynamic
data for the binding of RF-dendrimer conjugates to RfBP for
the series at N-3 and N-10 are shown in Tables 1 and 2.
In comparison with the “free” RF binding to RfBP (KD = 5
nM),16 the dissociation constant, KD for all dendrimer
conjugates screened is a factor of 93−1110 times greater.
This implies that the binding affinity of the dendrimerconjugated RF ligand to RfBP is significantly decreased.
Furthermore, the KD values in Tables 1 and 2 highlight the

basis of a simple sphere model where the dendrimer molecule
(d ≈ 6 nm) and the protein molecule (d ≈ 4 to 5 nm) are
treated as two interacting spheres, approximately 6 to 7 RfBPs
can be theoretically accommodated around the RF-conjugated
dendrimer particle. This analysis is in close agreement with the
maximal number (n ≈ 5; Tables 1 and 2) we obtained from
ITC measurements. Four dendrimer conjugates tethered at the
N-3 position of RF with an average RF valency of 0, 2.8, 4.5, or
11.1 were screened for determining their binding affinities to
RfBP (conjugates 3−6; Table 1). We also screened an
additional conjugate 7, which has an average of 11.1 RFs
linked at the N-3 position and contains an average number of
two fluorescein dye molecules as well. Three dendrimer
conjugates tethered at the N-10 position, which provides
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fact that the N-3-bound dendrimer series has an overall higher
affinity to RfBP in comparison with the RF-dendrimer
conjugates tethered at the N-10 position. Comparison of two
orthogonal conjugates 5 and 10, each having a similar average
number of RFs bound to the dendrimer but otherwise RF
attached at a different position N-3 or N-10, shows a factor of
∼5× greater KD value at the latter position. It clearly signifies
that contacts made in the binding pocket by the RF molecule
with a free ribose moiety are important and thus could lead to
tighter binding in the binding pocket. The magnitude of change
in free energy for the N-3 and N-10 series is comparable and
shows only a slight increase in free energy with increasing RF
valency for each series. To gain insight into the large differences
in affinity of the N-3 and N-10 RF-dendrimer conjugates to
RfBP, the enthalpic (ΔH) and the entropic (−TΔS)
contributions were examined and are shown in Figure 5. A
typical enthalpy−entropy compensation plot is also shown in

Figure 6. −TΔS versus ΔH (kJ/mol) scatter plot for the binding of
RF−dendrimer conjugates at N-3 and N-10 positions to RfBP at 25
°C. The linear regression is given by −TΔS (kJ·mol−1) = (−0.90 ±
0.03) ΔH (kJ·mol−1) − 30.0 ± 0.9 kJ·mol−1 (R2 = 0.9955, P < 0.0001).

dendrimer to verify the delivery of the payload. As such, we also
examined the binding of an N-3 dendrimer conjugate 7, which
included an average of 11.1 RFs and 2 FITC molecules. In the
latter case, the dissociation constant (KD) increased nearly twofold in comparison with an equivalent N-3 dendrimer conjugate
6, which included only an average of 11.1 RFs. This decrease in
affinity was accompanied by significant changes in both
enthalpy and entropy. An enthalpic penalty of 33.5 kJ/mol
and the entropic favorability for 7 relative to 6 highlights in this
case that the binding is enthalpy−entropy-driven. (See Figure
6.) These dramatic changes in both entropic and enthalpic
factors suggest that the mode of binding may have changed due
to the presence of the imaging molecule. Structurally both
FITC and RF are similar in that each contains three fused
aromatic rings, whereas the hydrophilic ribose moiety of the RF
is replaced by a hydrophobic moiety in FITC. The latter may
account for the significant changes in both entropic and
enthalpic factors. In contrast with the N-3 series, the binding of
N-10 dendrimer conjugates to RfBP shows an enthalpic
penalty, where the enthalpy is nearly a factor of 4−6 times
smaller in comparison with the N-3 dendrimer conjugates
(Table 2). However, the N-10 series of dendrimer conjugates
show a favorable entropic effect upon binding to RfBP in
comparison with the unfavorable entropic effects observed for
the N-3 series (Figure 5b). The enthalpic penalty observed for
the N-10 series of dendrimer conjugates is most likely due to
the desolvation of the ribose hydroxyl groups upon complexation with RfBP and the resulting release of water molecules
leading to an entropic gain.49 The binding affinity, however,
decreased by nearly a factor of 5 for the N-10 series, suggesting
that the enthalpy of interaction in the binding pocket between
the RF-dendrimer and the RfBP was not able to overcome the
enthalpic penalty arising from the desolvation of the polar
groups of the ribose moiety.49 This further implies that the RF
molecules bound at the N-10 position to the dendrimer lack
the optimal geometry required for binding to RfBP. Finally, as
in the N-3 series, the N-10 series of dendrimer conjugates also
show an increase in KD with increasing RF valency, suggesting
steric hindrance or repulsions between RF groups, due to
overcrowding on the dendrimer are likely to lead to a decrease
in affinity.34 In summary, the ITC study suggests that: (i) the
N-3 position of RF is a preferred position for the dendrimer
conjugation and (ii) presentation of targeting ligands at too

Figure 5. Thermodynamic parameters, including −TΔS, ΔH, and ΔG
representing the association of N-3 (a) and N-10 (b) RF dendrimer
conjugates with RfBP and with increasing valency of RF.

Figure 6 for both the N-3 and N-10 dendrimer conjugates, and
a strong linear correlation between the entropic and enthalpic
terms of the Gibbs equation is noted.47 For the N-3 dendrimer
conjugates, the enthalpy change is favorable, and the dendrimer
with an RF valency of 4.5 is the most favorable of the ligand
valencies examined (Table 1). By contrast, the entropic penalty
(−TΔS) increased from 4.8 to 20.4 kJ/mol for the N-3 RF
dendrimer conjugates with the highest entropic penalty
observed for the dendrimer with a valency of 4.5. This implies
that the binding of the N-3 series of RF dendrimer conjugates is
largely enthalpy driven, whereas the addition of RF units per
dendrimer results in an entropic penalty most likely due to
steric hindrance34,48 or repulsions arising from having RF
molecules in close proximity to the dendrimer. In addition to
using a dendrimer platform for targeted delivery of drug
conjugates, imaging molecules could also be attached to the
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Table 3. Shifts in Thermal Denaturationab

high valency such as n = 11 could prevent from achieving an
optimal affinity for individual RF ligands involved in the
receptor binding.
Because RF binding to RfBP is known to cause protein
structure stabilization,50,51 a DSC study was performed with
four RF conjugates 3, 5−7 to investigate the extent of structural
stability of RfBP upon binding to dendrimer−RF conjugates.
The DSC thermograms were also acquired for three other RF−
dendrimer conjugates 10−12 linked at the N-10 position,
which included those with an average of 4.0, 7.7, and 8.4 RF
molecules. Figure 7 demonstrates the effect on protein stability
of N-3 and N-10 conjugated dendrimers with an RF valency of

RfBP
RfBP+G5-(RF)0 3
N-3
RfBP+G5-(RF)4.5 5
RfBP+G5-(RF)11.1 6
RfBP+G5-(RF)11.1(FI)2 7
N-10
RfBP+G5-(RF)4.0 10
RfBP+G5-(RF)7.7 11
RfBP+G5-(RF)8.4 12

Tm
[°C]

ΔH
[kcal mol−1]

standard deviation
around fit

62.1
62.3

84.2
80.0

0.11
0.10

70.5
69.7
67.4

101.9
91.0
85.3

0.14
0.17
0.19

67.8
66.4
65.6

72.6
72.6
65.6

0.07
0.09
0.07

a

DSC experiments were performed in 10 mM phosphate buffer, pH
7.0. bProtein concentration was 1 mg/mL. Dendrimer conjugate
concentration was 140−325 uM.

than G5-RF11.1, a result also confirmed by ITC. Similarly, the
N-10 RF conjugated dendrimers show a decrease in RfBP
transition maximum from 67.8 to 65.6 °C with increasing RF
valency. However, a smaller enthalpy decrease is observed in
comparison with the N-3 bound dendrimers. Furthermore, the
enthalpy for unfolding with the N-10 dendrimer conjugates is
lower than the enthalpy of the apo-RfBP. Because the Tm values
for the N-10 dendrimer conjugates are higher than the Tm value
for apo-RfBP, enthalpy alone cannot explain the changes
observed here. The DSC data in combination with the ITC
results for the N-10 dendrimer conjugates demonstrate that
entropic factors play a key role in the binding of these RFdendrimer conjugates to RfBP. The decrease in Tm as the
number of RF molecules on the dendrimer is increased (for
both N-3 and N-10) corresponds well with ITC results, which
indicate that increasing the valency of RFs attached to the
dendrimer results in decreased binding strength. This negative
correlation of valency with the affinity constant might be due to
unfavorable constraints such as steric congestion34 that occurs
as more bulky receptors are recruited to the dendrimer surface.
In analyzing the receptor−ligand interactions from ITC and
DSC, we assume that all ligands attached to a single dendrimer
nanoparticle would have equivalent KD values. This is because
such binding affinities are determined from binding to free
RfBPs and in a manner independent of any of the constraints
that would occur if the identical dendrimer-linked RF ligands
bind to multiple RfBPs on a cell surface.7 However, in a cellbased receptor system, individual ligands attached to a single
dendrimer nanoparticle might have different KD values because
RfBPs are restricted in their location and lateral movement on
the cell surface.

Figure 7. Changes in denaturation temperature as a result of ligand
binding: apo RfBP; RfBP in complex with conjugate 10, G5-(RF)4.0
linked at the N-10 position; RfBP in complex with conjugate 5, and
G5-(RF)4.5 linked at the N-3 position. Protein concentration was 1
mg/mL in 10 mM phosphate buffer, pH 7.0. Scan rate was 1.0 °C
min−1 with temperature range 25−100 °C.

4.5 and 4.0, respectively. Apo-RfBP undergoes a reversible
endothermic transition with a maximum denaturation temperature (Tm) at 62.1 °C and is in close agreement with the 61.06
°C (Tm) obtained in previous DSC studies.52 Upon binding to
RfBP, the maximum of denaturation temperature of the RfBP
shifted to 67.8 °C for the conjugate 10, G5-(RF)4.0 N-10, and
to 70.5 °C for the conjugate 5, G5-(RF)4.5 N-3 (Figure 7). The
transition maximum for RfBP with a control conjugate 3, G5(RF)0, was 62.3 °C. These results demonstrate that the shift in
Tm observed is only due to the binding of RF-dendrimer
conjugates to the RfBP. The increase in denaturation
temperature of RfBP is dependent on the RF linker site: 5.7
°C for G5-(RF)4.0 N-10 and 8.4 °C for G5-(RF)4.5 N-3. These
DSC data correspond well with ITC data that suggest that the
binding affinity to RfBP is determined by how RF ligands are
linked to the dendrimer. Therefore, according to the ITC study,
the conjugate 5 with RF linked at the N-3 position showed
greater affinity than the conjugate 10, and the DSC study
showed that greater stability was achieved by the conjugate 5
with a Tm of 70.5 °C and an unfolding enthalpy of 101.9 kcal/
mol (Table 3). In comparison, the protein−ligand complex
formed between RfBP and free RF shows a Tm of 72.8 °C and
an unfolding enthalpy of 114.8 kcal/mol.51,52 Additionally, the
DSC data show that varying the valency of the RF molecules on
the dendrimer affects protein stability. As the average valency of
RF molecules attached to the dendrimer at N-3 increases from
4.5 to 11.1 the transition maximum of RfBP decreases from
70.5 to 67.4 °C, whereas the enthalpy for unfolding decreases
from 101.9 to 85.3 kcal/mol. (See Table 3.) This clearly
suggests that the G5-RF4.5 is more tightly bound to the RfBP

■

CONCLUSIONS
In conclusion, we have examined two new series of dendrimers,
each conjugated with RF ligands attached at the isoalloxazine
site (N-3) or the D-ribose site at (N-10) and with varying
average ligand valency. The binding of these RF−dendrimer
conjugates with RfBP were performed by ITC and DSC. The
KD values measured by ITC show that the RF ligand
conjugated to the dendrimer has an affinity much lower than
that of free RF toward the RfBP. Furthermore, the binding
affinity was found to decrease with increasing valency of RF on
the dendrimers. Of the two conjugate series, the RF linked at
the N-3 position showed greater affinity toward RfBP. These
results were independently confirmed by DSC, where greater
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protein−conjugate stability was achieved with the N-3 series
and at a lower ligand valency. In summary, the current
biophysical studies provide direct information on the strength
of discrete monovalent interactions that might constitute the
multivalent interaction. These studies should be complementary to cell-based avidity assays that investigate the targeting
capability of multivalent ligands based on a multivalent
binding.3−6 These results demonstrate the need to understand
and better design an optimized geometry for RF−dendrimer
conjugates to be used in targeted drug delivery.
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